What question did this study set out to answer?

To evaluate if EDAS can reduce rebleeding risk in adults with hemorrhagic moyamoya disease.

EXPRESS: Encephaloduroarteriosynangiosis Effectively Reduces Rebleeding Risk in Adults with Hemorrhagic Moyamoya Disease: A Long-Term Ambidirectional Cohort Study

View Full Paper

Ask AI

Bookmark

To evaluate if EDAS can reduce rebleeding risk in adults with hemorrhagic moyamoya disease.
Enrolled 186 adult patients with hemorrhagic moyamoya disease (hMMD).
Patients voluntarily chose between EDAS and conservative treatment.
Used Kaplan-Meier survival analysis and Cox regression to assess rebleeding risks.
In the EDAS group, 16 patients (13.0%) had recurrent hemorrhage vs. 18 patients (28.6%) in conservative treatment (P=0.015).
Annual rebleeding incidence was 1.4% in EDAS group vs. 3.6% in conservative group (P=0.005).
Three patients (2.4%) died from rebleeding in EDAS group compared to seven (11.1%) in conservative group (P=0.033).

No takes yet. Share an insight, caveat, or question.

Cohort study investigates EDAS impacts on rebleeding rates in adults with hemorrhagic moyamoya disease, suggesting effective reduction.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark